Oramed announces $20M share repurchase plan

Oramed Pharmaceuticals announced that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20M in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.